X4 Pharmaceuticals (NASDAQ: XFOR) reported Q1 EPS of $0.04, $0.16 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $28.81 million versus the consensus estimate of $12.03 million.

For earnings history and earnings-related data on X4 Pharmaceuticals (XFOR) click here.